Wegovy for Weight Loss: What You Need To Know
Wegovy, a once-weekly injectable medication (semaglutide), is approved to treat obesity and excess weight – conditions that can lead to type 2 diabetes and prediabetes.
Obesity is a complicated and serious chronic condition that can lead to many other complications – including type 2 diabetes, prediabetes, and heart disease. Roughly 40% of adults in the U.S. live with obesity, defined as a body mass index (BMI) over 30. However, most people with obesity are undiagnosed, and less than 3% have been prescribed a medicine to help them manage their condition. Although obesity and excess weight can lead to type 2 diabetes and prediabetes, weight management can reduce that risk, preventing or delaying the onset of these diseases.
In 2021, the FDA approved Novo Nordisk’s Wegovy (generic name semaglutide), a once-weekly injection for chronic weight management. In 2025, Wegovy became the first GLP-1 for weight loss to be approved as an oral, once-daily pill. Both formulations are approved for people with obesity (BMI greater than 30) or excess weight (BMI greater than 27) who also have at least one other weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol. The drug is used in combination with a reduced-calorie meal plan and increased physical activity to support weight loss.
“The approval of Wegovy provides the availability of a more effective medication for the management of obesity and sets the stage for a new generation of drugs that harness the benefits of naturally occurring hormones such as GLP-1,” said Dr. Robert Kushner from Northwestern University, who was an author on the research papers that led to Wegovy’s approval.
Semaglutide, a GLP-1 receptor agonist drug, is also approved in the U.S. to treat type 2 diabetes as a once-weekly injection (Ozempic) and as a tablet taken orally (Rybelsus). In addition to improving diabetes management, Ozempic and Rybelsus also support heart health. Ozempic is specifically approved to reduce the risk of serious heart problems, including heart attacks, strokes, and heart-related deaths in adults with type 2 diabetes and heart disease. Following in Ozempic's footsteps, Wegovy was approved in 2024 to reduce the risk of heart disease and stroke in people with obesity. Semaglutide has also been shown to be beneficial for kidney health, with the FDA approving Ozempic for chronic kidney disease in people with type 2 diabetes in 2025.
Wegovy dosing
Currently, the highest approved dose of Ozempic for blood sugar management is 2.0 mg per week. Wegovy is available at a slightly higher dose than 2.4 mg, with clinical research showing an average of 15% weight loss after 16 months. In addition, roughly 84% of study participants taking Wegovy were able to lose at least 5% of their body weight compared to 31% of those not taking Wegovy.
The starting dose of Wegovy is 0.25 mg weekly, which is gradually increased until a maintenance dose of either 1.7 or 2.4 mg is reached. What dose works for you depends on your weight management goals and what's recommended by your healthcare team. Having additional dosing options gives healthcare providers and people with diabetes an opportunity to personalize treatment based on their health goals.
Newer research has also been investigating whether a higher dose of Wegovy can help people with obesity who aren’t able to achieve their weight loss goals on the current approved doses. A recent 2025 study testing a higher 7.2 mg dose of semaglutide (not yet approved) in people with obesity found that it was more effective for weight loss compared to the 2.4 mg dose. Participants taking the 7.2 mg dose achieved an average of roughly 19% weight loss compared to 16% on 2.4 mg after 72 weeks.
Though more effective for weight management, the 7.2 mg dose also caused more side effects, including nausea, vomiting, and constipation, compared to the 2.4 mg dose. More research needs to be done on feasibility, as some people may not tolerate more frequent or intense side effects with the higher GLP-1 dose.
How to get Wegovy
Wegovy is available with a prescription for people with overweight or obesity who qualify. It's available in many countries worldwide, including the U.S., Canada, and Europe. In the U.S., the cost of the drug may vary depending on whether you have health insurance – many do, but not all health insurance covers obesity treatment. Some people without insurance may qualify for a $25 monthly co-pay assistance program.
The bottom line
Treating obesity and excess weight as chronic conditions could help prevent people from developing type 2 diabetes and other health complications. New types of treatment for weight management like Wegovy may also help address the stigma around diabetes and obesity – neither condition is a lifestyle choice nor personal flaw, but rather are medical conditions that involve a number of factors, including genetics and environment.
Learn more about weight management treatment here: